Post-approval changes (PAC) for medicinal products have increased rapidly in recent years, and faster than national regulatory authorities (NRAs) can reliably cope with. This is both a concern and a challenge for Latin American countries. The World Health Organization (WHO) has recently published two documents that will be critical for countries\u2019 regulatory system strengthening activities, including regulatory cooperation, convergence and transparency.<\/p>\n\n\n\n